A Registered Cohort Study of Immune-Mediated Neuropathies
NCT ID: NCT04292834
Last Updated: 2021-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2020-02-29
2025-01-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Autoimmune Disease of Nervous System
NCT06502015
National, Multicentric Registry Study on Neuroimmunological Diseases in China
NCT06443333
A Prospective Cohort Study of Myasthenia Gravis in China
NCT06006832
The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies
NCT03864185
Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
NCT01655394
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
4\. Age 18 or above
Exclusion Criteria
2. Poor prognosis (\<1 year survival)
3. Severe mental disorder and inability to cooperate with the examination.
4. Age less than 18
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Tiantan Hospital
OTHER
First Affiliated Hospital of Fujian Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ning Wang, MD., PhD.
Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Department of Neurology,First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Zaiqiang Zhang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MRCTA，ECFAH of FMU2019217
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.